Background Image Background Image

Single-Molecule NanoAnalyzer

Redefining sensitivity with advanced single-photon counting module, designed to detect individual drug payloads and particle markers with precision.

EV analytical accuracy with unmatched sensitivity and lowest background

  • EV size, concentration, and biomarkers—all in a single run

  • Contaminant detection and purification assessment

  • Epitope mapping and drug loading optimization

Test the Integrity and Performance of your Viral Vector biotherapeutics with confidence

  • Size and concentration

  • Vector loading ratio

  • Multiparameter component analysis

  • Evaluate vector integrity

  • Enumerate functional vectors from empty capsids

Optimize formulation and delivery performance of mRNA-LNPs

  • Size and concentration

  • Loading ratio and encapsulation efficiency

  • mRNA distribution and surface ligand analysis

Ensuring efficacy and consistency of EV-based vaccines

  • Size and concentration

  • Empty / Full ratio

  • Antigen quantification

  • Stability tracking

Single-Molecule NanoAnalyzer
EV analytical accuracy with unmatched sensitivity and lowest background
Test the Integrity and Performance of  your Viral Vector biotherapeutics with confidence
Optimize formulation and delivery performance of mRNA-LNPs
Ensuring efficacy and consistency of EV-based vaccines
team_img
Accelerating In Vivo CAR-T Development Using Single Nanoparticle Characterization  :

Join us for a cutting-edge GEN webinar with nanoparticle delivery expert Joseph Brealey as he explores how in vivo CAR T cell engineering is overcoming the limits of traditional ex vivo manufacturing. Discover how NanoFCM’s single-molecule NanoAnalyzer is transforming quality control, offering label-free LNP sizing, mRNA loading and targeting ligand high precision quantitative analysis, all in a single run. Learn how these insights can unlock higher in vivo transfection efficiency and accelerate CAR T breakthroughs. Stick around for a live Q&A to get your questions answered by the expert himself!

Date : 

Thursday, July 24, 2025

Time : 

8:00 am PT | 11:00 am ET | 17:00 CEST

team_img
team_img
team_img
team_img
team_img
team_img
team_img
team_img
team_img
team_img
team_img
team_img
team_img

EXTRACELLULAR VESICLES

THE ORIGIN AND PHENOTYPING OF EXTRACELLULAR VESICLES

team_img

VACCINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

team_img

NANOMEDICINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

team_img

BACTERIA DETECTION

TRULY QUANTITATIVE MEASUREMENT OF TOTAL BACTERIAL TITRE

team_img

VIRUSES/VIRAL VACCINE

INTEGRATE INTO THE GENOMES OF THE HOST CELLS

team_img

OTHERS

COMPREHENSIVE MEASUREMENT SUITE FOR NANOPARTICLES AND INDIVIDUAL MITOCHONDRIA

team_img

EXTRACELLULAR VESICLES

THE ORIGIN AND PHENOTYPING OF EXTRACELLULAR VESICLES

DETAILS
team_img

VACCINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

DETAILS
team_img

NANOMEDICINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

DETAILS
team_img

BACTERIA DETECTION

TRULY QUANTITATIVE MEASUREMENT OF TOTAL BACTERIAL TITRE

DETAILS
team_img

VIRUSES/VIRAL VACCINE

INTEGRATE INTO THE GENOMES OF THE HOST CELLS

DETAILS
team_img

OTHERS

COMPREHENSIVE MEASUREMENT SUITE FOR NANOPARTICLES AND INDIVIDUAL MITOCHONDRIA

DETAILS
team_img

EXTRACELLULAR VESICLES

THE ORIGIN AND PHENOTYPING OF EXTRACELLULAR VESICLES

team_img

VACCINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

team_img

NANOMEDICINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

team_img

BACTERIA DETECTION

TRULY QUANTITATIVE MEASUREMENT OF TOTAL BACTERIAL TITRE

team_img

VIRUSES/VIRAL VACCINE

INTEGRATE INTO THE GENOMES OF THE HOST CELLS

team_img

OTHERS

COMPREHENSIVE MEASUREMENT SUITE FOR NANOPARTICLES AND INDIVIDUAL MITOCHONDRIA

For many years scientists yearned for the possibility of performing flow cytometry to analyse small bio-nanoparticles that are too small to be measured by conventional and high sensitivity instruments. These entities, extracellular vesicles, gene therapy vectors, viruses and drug delivery particles, are promised to become the next generation of therapeutics, but they have been hard to handle and characterise due to their small size and biological or chemical heterogeneity. There is therefore a strong case for bringing flow cytometry capability to the sub-200nm scale.

NanoFCM has developed the NanoAnalyzer platform that now enables true flow-cytometry measurement at the sub-micron scale, and down to particle sizes unreachable by any other flow cytometers (10-40nm depending on the nature of the substrate). Nano-flow cytometry, the technology that underpins the NanoAnalyzer, removes bias and uncertainty stemming from the use of fluorescence signal triggering by using its highly sensitive side-scatter channel to trigger particle events. The single-particle nature of the measurement prevents uncontrolled swarming events, reinforcing data integrity. High resolution of both scatter and fluorescence channels allows the assessment of subpopulations, based on size or on bio-chemical properties.

Nano-flow cytometry’s ability to measure simultaneously a (bio)-nanoparticle population for size, size distribution and bio-chemical properties on a single instrument dramatically improves data quality and throughput compared to the traditional, multiple-techniques approach involving particle characterisation and counting (DLS, NTA, RPS), combined with chemical and biological function assessment (ELISA, Western Blot, Flow Cytometry, PCR). Quantitative measurement of the active and contaminant particles in a single preparation opens up the possibility of characterisation-based nanomedicine regulatory approval, and allows the conduct of large-scale clinical studies. From the research laboratory to the quality control department, NanoFCM delivers comprehensive bio-nano analysis.